Loading
A phase 2 trial of Sacituzumab tirumotecan in thymoma and thymic carcinoma, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma is a phase 2 interventional study registered as NCT07324629 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 30 participants planned, started 2026-03-13 and due to reach its primary completion in 2028-04. Interventions recorded: Sacituzumab tirumotecan.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Thymic carcinoma, Thymoma and thymic carcinoma and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Thymic carcinoma, Thymoma and thymic carcinoma and the tag pipeline.
Shares Thymic carcinoma, Thymoma and thymic carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/